Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #149611 on Innovation Pharmaceuticals Inc (IPIX)
winnail
05/31/16 3:24 PM
#149614 RE: sox040713 #149611
TheHound
05/31/16 3:30 PM
#149616 RE: sox040713 #149611
What is in question are the elements of QIDP fast-rack that will be applied. At least one and possibly up to all of the following are possible and will result from the FDA Phase 2 meeting. Accelerated review only. (Reduces the review time between trials from > 10 months to ~ 6 months) Rolling review Surrogate endpoints FDA intensive guidance and organizational commitment 60 day FDA responses The trifecta: rolling review with surrogate endpoints, intensive guidance and organizational commitment, 60 day BLA and NDA guaranteed response time. Also, some of the elements depend on a sponsors ability to guarantee rapid marketing and product quality after approval. In CTIX's case that will require a partner or license.
Amatuer17
06/01/16 8:29 PM
#149722 RE: sox040713 #149611